ArticleFrontiers in oncology2026
Elevated FGR protein expression identifies a high-risk subset of diffuse large B-cell lymphoma and a potential therapeutic target.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma, and despite effective first-line immunochemotherapy a substantial proportion of patients develop relapse/refractory (RR) disease, underscoring the need for practical biomarkers beyond clinical risk scores. Methods: We retrospectively evaluated FGR protein expression by immunohistochemistry (IHC) in 91 patients with Results: High FGR expression was observed in 64 of 91 tumors (70.3%) and was associated with a higher 5-year RR rate (29.7% vs 7.4%, P = 0.021). In Kaplan-Meier analyses, progression-free survival (PFS) was 69.1% in the high-expression group versus 92.1% in the low-expression group (P = 0.093), and overall survival (OS) was 80.0% versus 96.2% (P = 0.050); separation was more pronounced in the non-germinal center B-cell (non-GCB) subgroup. In multivariable Cox regression, high FGR remained independently associated with inferior 5-year PFS (HR 4.73, 95% CI 1.03-21.65; P = 0.045) and showed a strong trend toward inferior 5-year OS (HR 6.52, 95% CI 0.79-53.99; P = 0.082). ROC analysis suggested that FGR and IPI had similar discrimination at 5 years in this cohort. In external validation, FGR mRNA expression was elevated in non-GCB cases, and high FGR expression (upper quartile) was associated with a trend toward inferior OS. Conclusion: Elevated FGR protein expression identifies a subset of DLBCL patients with increased treatment failure and inferior outcomes, particularly within non-GCB subtypes, supporting prospective validation in larger, less selected cohorts and further mechanistic studies of the FGR/Src-family kinase axis as a candidate therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.